CN100347172C - 作为因子Xa抑制剂的氮杂吲哚衍生物 - Google Patents

作为因子Xa抑制剂的氮杂吲哚衍生物 Download PDF

Info

Publication number
CN100347172C
CN100347172C CNB2004800139362A CN200480013936A CN100347172C CN 100347172 C CN100347172 C CN 100347172C CN B2004800139362 A CNB2004800139362 A CN B2004800139362A CN 200480013936 A CN200480013936 A CN 200480013936A CN 100347172 C CN100347172 C CN 100347172C
Authority
CN
China
Prior art keywords
pyridine
hydrocarbyl
pyrrolo
chloro
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800139362A
Other languages
English (en)
Chinese (zh)
Other versions
CN1791601A (zh
Inventor
M·纳扎雷
V·魏纳
D·W·威尔
K·里特
M·乌尔曼
H·马特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN1791601A publication Critical patent/CN1791601A/zh
Application granted granted Critical
Publication of CN100347172C publication Critical patent/CN100347172C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB2004800139362A 2003-05-19 2004-05-05 作为因子Xa抑制剂的氮杂吲哚衍生物 Expired - Fee Related CN100347172C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011304.7 2003-05-19
EP03011304A EP1479680A1 (en) 2003-05-19 2003-05-19 Azaindole derivatives as Factor Xa inhibitors

Publications (2)

Publication Number Publication Date
CN1791601A CN1791601A (zh) 2006-06-21
CN100347172C true CN100347172C (zh) 2007-11-07

Family

ID=33040951

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800139362A Expired - Fee Related CN100347172C (zh) 2003-05-19 2004-05-05 作为因子Xa抑制剂的氮杂吲哚衍生物

Country Status (24)

Country Link
EP (2) EP1479680A1 (https=)
JP (1) JP4733642B2 (https=)
KR (1) KR20060012636A (https=)
CN (1) CN100347172C (https=)
AR (1) AR045682A1 (https=)
AU (1) AU2004238500B2 (https=)
BR (1) BRPI0410429A (https=)
CA (1) CA2526084A1 (https=)
CL (1) CL2004001079A1 (https=)
CR (1) CR8088A (https=)
EC (1) ECSP056179A (https=)
MA (1) MA27799A1 (https=)
MX (1) MXPA05012156A (https=)
NO (1) NO20055911L (https=)
NZ (1) NZ543669A (https=)
OA (1) OA13169A (https=)
PE (1) PE20050554A1 (https=)
RS (1) RS20050857A (https=)
RU (1) RU2330853C2 (https=)
TN (1) TNSN05296A1 (https=)
TW (1) TW200510411A (https=)
UA (1) UA86767C2 (https=)
WO (1) WO2004101563A1 (https=)
ZA (1) ZA200508150B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351940T3 (es) * 2005-11-18 2011-02-14 F. Hoffmann-La Roche Ag Derivados de azaindol-2-carboxamida.
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
IN2015DN01061A (https=) 2012-08-17 2015-06-26 Bayer Cropscience Ag
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111834531B (zh) * 2019-04-15 2022-04-19 天津大学 一种有机半导体材料、制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033800A1 (en) * 1997-12-24 1999-07-08 Aventis Pharma Deutschland Gmbh Indole derivatives as inhibitors or factor xa
WO2001064639A2 (en) * 2000-03-02 2001-09-07 Merck Frosst Canada & Co. Pde iv inhibiting amides, compositions and pharmaceutical use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1241472B (it) 1990-07-06 1994-01-17 Olivier Linda Dispositivo elettromeccanico per la cattura continua in particolare di topi e ratti.
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
SI9520044B (sl) 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
ZA964008B (en) * 1995-06-02 1997-07-11 Akzo Nobel Nv Imidazo[1,5a]pyridine derived serine protease inhibitors
EP1040108B1 (en) * 1997-12-19 2004-02-25 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
JP4241970B2 (ja) * 1998-10-30 2009-03-18 中外製薬株式会社 アミド結合を有するインドール誘導体、及びモノ又はジアザインドール誘導体
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE60040676D1 (de) * 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
JP2001294572A (ja) * 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
US6790845B2 (en) * 2001-04-09 2004-09-14 Bristol-Myers Squibb Pharma Company Fused heterocyclic inhibitors of factor Xa
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
KR100960827B1 (ko) * 2001-12-20 2010-06-08 오에스아이 파마슈티컬스, 인코포레이티드 피롤로피리미딘 Ａ₂ｂ 선택성 길항 화합물, 그의 합성방법 및 용도
DE10214832A1 (de) * 2002-04-04 2003-10-16 Merck Patent Gmbh Phenylderivate 4
JP2004203791A (ja) * 2002-12-25 2004-07-22 Dai Ichi Seiyaku Co Ltd 芳香族化合物
JP2004210716A (ja) * 2002-12-27 2004-07-29 Dai Ichi Seiyaku Co Ltd ジアミド誘導体
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033800A1 (en) * 1997-12-24 1999-07-08 Aventis Pharma Deutschland Gmbh Indole derivatives as inhibitors or factor xa
WO2001064639A2 (en) * 2000-03-02 2001-09-07 Merck Frosst Canada & Co. Pde iv inhibiting amides, compositions and pharmaceutical use

Also Published As

Publication number Publication date
JP4733642B2 (ja) 2011-07-27
OA13169A (en) 2006-12-13
JP2006528214A (ja) 2006-12-14
AU2004238500A1 (en) 2004-11-25
KR20060012636A (ko) 2006-02-08
EP1479680A1 (en) 2004-11-24
MXPA05012156A (es) 2006-08-18
MA27799A1 (fr) 2006-03-01
NO20055911L (no) 2006-02-10
AU2004238500B2 (en) 2010-07-22
TNSN05296A1 (en) 2007-07-10
ZA200508150B (en) 2007-02-28
HK1089175A1 (zh) 2006-11-24
RU2005139557A (ru) 2007-06-27
CA2526084A1 (en) 2004-11-25
BRPI0410429A (pt) 2006-06-06
CR8088A (es) 2006-09-22
CL2004001079A1 (es) 2005-04-08
UA86767C2 (ru) 2009-05-25
RS20050857A (sr) 2007-11-15
RU2330853C2 (ru) 2008-08-10
WO2004101563A1 (en) 2004-11-25
NZ543669A (en) 2008-12-24
EP1636226B1 (en) 2014-10-15
CN1791601A (zh) 2006-06-21
AR045682A1 (es) 2005-11-09
PE20050554A1 (es) 2005-08-04
ECSP056179A (es) 2006-08-30
EP1636226A1 (en) 2006-03-22
TW200510411A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
CN1283638C (zh) 作为因子Xa抑制剂的吲哚－2－甲酰胺化合物
CN1168727C (zh) 取代的苯并咪唑
CN1926137A (zh) 作为Xa因子抑制剂的吡咯衍生物
JP4676960B2 (ja) 第Ｘａ因子阻害剤としてのインドール誘導体
CN1098263C (zh) 吡啶－2－基－甲胺衍生物、其制备方法及其作为药物的用途
CN100337626C (zh) 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途
US20080280946A1 (en) Azaindole-Derivatives As Factor Xa Inhibitors
CN1993359A (zh) 杂环取代的环状脲衍生物、其制备及其作为激酶抑制剂的药物用途
US7223780B2 (en) Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
CN1642938A (zh) 新化合物
CN1633433A (zh) N－芳酰基环胺
CN1204327A (zh) 药用活性喹唑啉类化合物
CN1175259A (zh) 低分子量双环凝血酶抑制剂
CN1934112A (zh) 稠合的杂环化合物及其作为代谢型谷氨酸受体拮抗剂的应用
CN1674893A (zh) 苯并咪唑衍生物
CN1856477A (zh) 异喹啉钾通道抑制剂
CN1950357A (zh) 用作tafia抑制剂的咪唑衍生物
CN1926148A (zh) 用作Xa因子抑制剂的β－氨基酸衍生物
CN100347172C (zh) 作为因子Xa抑制剂的氮杂吲哚衍生物
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1374960A (zh) 新的整联蛋白受体拮抗剂
JP4608495B2 (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
CN1062266C (zh) 脒衍生物以及含有该衍生物的血小板聚集抑制剂
CN100484935C (zh) 作为因子Xa抑制剂的苯并咪唑衍生物
CN1173957C (zh) 取代的哌嗪酮及其治疗应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1089175

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1089175

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071107

Termination date: 20110505